Latest filing published 23 Jun 2025 for Zai Lab Ltd. Read the official filing
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Peter Wirth (board member) discloses dealings in 3 companies, chiefly Zai Lab Ltd, Forma Therapeutics Holdings, Inc. and Syros Pharmaceuticals, Inc. In total, 13 filings cover trades dated from 17 June 2021 to 18 June 2025.
Both buying and selling appear: 2 purchases worth €506k, against 1 sale worth €130k. Purchases outweigh sales by €377k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Other entries cover 9 share grants.
Most recently, on 23 June 2025, the filings show a share grant in Zai Lab Ltd. The last insider purchase was made public on 12 December 2022, 1,406 days ago. Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
13 of 13 declarations